4.42

1.34% -0.06

Adaptive Biotechnologies Corp (ADPT)

Overview News Price History Option Chain Financials Why ADPT Down? Discussions Forecast

Adaptive Biotechnologies Corp stock is traded at $4.42, with a volume of 1.81M. It is down -1.34% in the last 24 hours and down -5.56% over the past month. Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

Previous Close:

$4.48

Open:

$4.42

24h Volume:

1.81M

Relative Volume:

1.75

Market Cap:

$652.30M

Revenue:

$170.28M

Net Income/Loss:

$-225.25M

P/E Ratio:

-3.3233

EPS:

-1.33

Net Cash Flow:

$-167.02M

1W Performance:

-24.44%

1M Performance:

-5.56%

6M Performance:

+23.12%

1Y Performance:

-0.45%

1-Day Range:

$4.33

$4.565

1-Week Range:

$4.33

$5.95

52-Week Range:

$2.28

$6.70

Adaptive Biotechnologies Corp Stock (ADPT) Company Profile

Name

Adaptive Biotechnologies Corp

Sector

Healthcare (1193)

Industry

Biotechnology (683)

Phone

206-659-0067

Address

1165 EASTLAKE AVE E, SEATTLE, WA

Employee

709

Twitter

@adaptivebiotech

Next Earnings Date

2024-11-07

Latest SEC Filings

ADPT's Discussions on Twitter

Compare ADPT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ADPT	4.42	652.30M	170.28M	-225.25M	-167.02M	-1.33
VRTX	451.23	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	743.35	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	591.82	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.79	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.14	24.49B	3.30B	-501.07M	1.03B	11.54

Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-05-23	Resumed	JP Morgan	Overweight
Jan-05-23	Initiated	Scotiabank	Sector Outperform
Dec-21-22	Upgrade	Piper Sandler	Neutral → Overweight
Aug-25-22	Initiated	Credit Suisse	Underperform
Jun-03-22	Initiated	Piper Sandler	Neutral
Feb-16-22	Reiterated	BTIG Research	Buy
Feb-16-22	Reiterated	BofA Securities	Buy
Feb-16-22	Reiterated	Goldman	Neutral
Feb-16-22	Reiterated	JP Morgan	Overweight
Oct-15-21	Resumed	Cowen	Outperform
Mar-03-21	Downgrade	Goldman	Buy → Neutral
Oct-08-20	Resumed	BTIG Research	Buy
Sep-09-20	Initiated	Morgan Stanley	Equal-Weight
Jun-03-20	Initiated	Goldman	Buy
Jul-23-19	Initiated	BTIG Research	Buy
Jul-22-19	Initiated	BofA/Merrill	Buy
Jul-22-19	Initiated	Cowen	Outperform
Jul-22-19	Initiated	Goldman	Neutral
Jul-22-19	Initiated	Guggenheim	Buy
Jul-22-19	Initiated	William Blair	Outperform

View All

Adaptive Biotechnologies Corp Stock (ADPT) Latest News

Nov 20, 2024

Adaptive Biotechnologies (FRA:1HM) Operating Margin % : -70.27% (As of Sep. 2024) - GuruFocus.com

Nov 20, 2024

Tarsus Pharmaceuticals (NASDAQ:TARS) versus Adaptive Biotechnologies (NASDAQ:ADPT) Financial Survey - Defense World

Nov 20, 2024

Nov 19, 2024

Adaptive Biotechnologies' CFO Kyle Piskel sells $1,235 in shares By Investing.com - Investing.com Nigeria

Nov 19, 2024

Adaptive Biotechnologies' CFO Kyle Piskel sells $1,235 in shares - Investing.com India

Nov 19, 2024

Nov 18, 2024

Adaptive Biotechnologies Corp: Is ADPT Stock Worth Buying? - Stocks Register

Nov 18, 2024

William Blair Has Bullish Forecast for ADPT FY2024 Earnings - MarketBeat

Nov 18, 2024

Adaptive Biotechnologies Co. (NASDAQ:ADPT) Sees Significant Decrease in Short Interest - MarketBeat

Nov 18, 2024

Nov 15, 2024

Wall Street Analysts Predict a 31.36% Upside in Adaptive Biotechnologies (ADPT): Here's What You Should Know - Yahoo Finance

Nov 15, 2024

Nov 13, 2024

Rubric Capital Management LP's Strategic Acquisition in Adaptive Biotechnologies Corp - GuruFocus.com

Nov 13, 2024

Matrix Capital Management Reduces Stake in Adaptive Biotechnologies Corp - GuruFocus.com

Nov 13, 2024

Nov 12, 2024

Adaptive Biotechnologies (NASDAQ:ADPT) Trading Up 12.7% Following Analyst Upgrade - Defense World

Nov 12, 2024

Nov 11, 2024

Adaptive Biotechnologies (NASDAQ:ADPT) Trading 12.7% Higher After Analyst Upgrade - MarketBeat

Nov 11, 2024

Adaptive Biotechnologies (NASDAQ:ADPT) Price Target Raised to $7.00 - MarketBeat

Nov 11, 2024

Nov 10, 2024

ADPT (Adaptive Biotechnologies) Cash From Other Investing A - GuruFocus.com

Nov 10, 2024

Nov 09, 2024

Adaptive Biotechnologies Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 09, 2024

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 09, 2024

Nov 08, 2024

Nikko Asset Management Americas, Inc. Expands Stake in Adaptive Biotechnologies Corp - GuruFocus.com

Nov 08, 2024

Earnings call: Adaptive Biotechnologies posts robust MRD revenue growth - Investing.com

Nov 08, 2024

ARK Investment Management LLC Buys 189,134 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat

Nov 08, 2024

Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - MSN

Nov 08, 2024